| Vaccine description | |
|---|---|
| Target | SARS-CoV-2 |
| Vaccine type | mRNA |
| Clinical data | |
| Other names | LUNAR-COV19 |
| Routes of administration | Intramuscular |
ARCT-021, also known as LUNAR-COV19, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics.
It requires the intramuscular injection with a single dose.[1]
ARCT-021 is an mRNA vaccine.[2]
Arcturus Therapeutics partnered with Singapore's Duke–NUS Medical School to develop a COVID-19 vaccine.[3] The company also partnered with Catalent, a contract development and manufacturing organization, to manufacture multiple batches of Arcturus' COVID-19 mRNA vaccine candidate.[4]
LUNAR-COV19 clinical trials in humans began in July 2020.[5] On 4 January 2021, Arcturus Therapeutics started Phase-2 clinical trials.[6]
Arcturus has entered into development and supply agreements with the Economic Development Board of Singapore and supply agreements with the Israel Ministry of Health for LUNAR-COV19.[7][8]
|
| |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Development |
| ||||||||||
| Classes |
| ||||||||||
| Administration |
| ||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers |
| ||||||||||
| Controversy |
| ||||||||||
| Related |
| ||||||||||
| |||||||||||
Viruses
COVID-19 | This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it. |
 | This article about vaccinesorvaccination is a stub. You can help Wikipedia by expanding it. |
